article thumbnail

COVID-19 Associated with Increased Risk of Cardiovascular Events

Drug Topics

A study published in Arteriosclerosis, Thrombosis, and Vascular Biology found the risk of major adverse cardiac events was higher in patients hospitalized with COVID-19.

Hospitals 123
article thumbnail

Study Reveals Robust Benefits of Semaglutide in Protecting Against Kidney, CV Events in Patients With T2D

Drug Topics

Semaglutide reduced the risk of major kidney disease and cardiovascular (CV) events, and death from any cause, while simultaneously decelerating the loss of kidney function, among patients with type 2 diabetes (T2D) and CKD compared to placebo.

211
211
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

COVID-19 Hospital Burden Associated With Increased Inpatient Adverse Events Among Patients With and Without COVID-19

Pharmacy Times

High COVID-19 hospital caseload strain led to increases in inpatient adverse events among patients both with and without SARS-CoV-2 infection.

Hospitals 132
article thumbnail

FlyPharma Vienna 2024: An Event to Remember!

Pharmafile

As a landmark event, FlyPharma Vienna 2024 has successfully wrapped, marking a pivotal gathering of industry professionals, expert speakers and delegates, from notable companies such as Sanofi, Takeda, Bayer, Amgen, Octapharma, Lufthansa, IATA, DHL, DoKaSch, Kühne + […] The post FlyPharma Vienna 2024: An Event to Remember!

59
article thumbnail

Events

Blog: Ask a Student Pharmacist

Events pbhamidi Mon, 09/30/2024 - 22:19 - Any - In-Person Virtual There are no events to show

52
article thumbnail

Understanding Adverse Events With BCMA-, Non-BCMA-Targeting Bispecific Antibodies in Multiple Myeloma

Drug Topics

Understanding the adverse event profile of bispecific antibodies can aid treatment selection and improve patient outcomes.

200
200
article thumbnail

BTK Inhibitor-Associated Adverse Events

Pharmacy Times

The discussion explores the evolution of understanding adverse events (AEs) related to Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia treatment and identifies the primary classwide AEs associated with these therapies.

65